The rapidity with which bone and cartilage damage occurs in patients with rheumatoid
arthritis (RA), and the increasing body of evidence for the effectiveness of early intervention
in RA, mean that there is a great need for approaches to accurately predict the development
of RA in patients with early undifferentiated arthritis. We will review developments in the
prediction of outcome on the basis of clinical and laboratory features, including measures of
anti-citrullinated protein/peptide antibody status. Although accurate predictions are possible …